Myriad Genetics, Inc. (NASDAQ:MYGN) is looking for suitable acquisition targets to sustain its business as threats from rivals in the market rise, consequently leading analysts and investors to believe that the company’s market share would decline eventually.
Myriad has been among the most successful firms dealing with DNA testing across the globe. However, two years ago, the Salt Lake City-based company faced a major setback when the Supreme Court rejected its gene patents, after which the company could not patent the human DNA.
Help employers find you! Check out all the jobs and post your resume.
Myriad has been among the most successful firms dealing with DNA testing across the globe. However, two years ago, the Salt Lake City-based company faced a major setback when the Supreme Court rejected its gene patents, after which the company could not patent the human DNA.
Help employers find you! Check out all the jobs and post your resume.
